Smither John W — SEC insider filings
SEC reporting owner CIK 1559583. 32 insider filings on record with FilingPulse; latest filed 2026-09-09.
Transaction summary — filings shown
Covers all 32 filings on record, filed 2020-10-01 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 6,250 shares.
- Open-market sales (code S, non-derivative): 16 legs across 10 filings — 33,523 shares, $713,637 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 51.
- Largest priced transaction: sale of 3,750 shares @ $35.00 ($131,250) in Arcutis Biotherapeutics, Inc., filed 2021-02-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | Chief Financial Officer | 10 | — | 13 legs · 19,023 sh · $619,525 | 21 |
| GENELUX Corp (GNLX) | Director | 8 | 1 leg · 6,250 sh | 2 legs · 12,900 sh · $53,600 | 10 |
| NewAmsterdam Pharma Co N.V. (NAMS) | Director | 4 | — | 1 leg · 1,600 sh · $40,512 | 5 |
| eFFECTOR Therapeutics, Inc. (EFTR) | Director | 5 | — | — | 7 |
| Applied Molecular Transport Inc. (AMTI) | Director | 4 | — | — | 6 |
| MBX Biosciences, Inc. (MBX) | Chief Financial Officer | 1 | — | — | 2 |
Insider filings — Smither John W
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Sale (S): 1,600 @ $25.32 | EDGAR |
| 2026-08-04 | 4 | MBX Biosciences, Inc. (MBX) | Grant/award (A): 28,000 @ $0 · Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | GENELUX Corp (GNLX) | Sale (S): 12,000 @ $2.91 | EDGAR |
| 2026-06-18 | 4 | GENELUX Corp (GNLX) | Grant/award (A): 28,409 @ $0 · Grant/award (A): 31,566 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 3,400 · Grant/award (A): 15,300 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | GENELUX Corp (GNLX) | Grant/award (A): 22,283 @ $0 · Grant/award (A): 28,576 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 6,960 · Grant/award (A): 32,500 (derivative) @ $0 | EDGAR |
| 2024-12-31 | 4/A | GENELUX Corp (GNLX) | Grant/award (A): 50,469 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | GENELUX Corp (GNLX) | Grant/award (A): 39,541 @ $0 · Grant/award (A): 50,469 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | GENELUX Corp (GNLX) | Purchase (P): 6,250 · Purchase (P): 6,250 (derivative) | EDGAR |
| 2024-02-15 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 2,793 · Grant/award (A): 8,572 · Disposition to issuer (D): 8,379 (derivative) · Disposition to issuer (D): 25,718 (derivative) | EDGAR |
| 2024-01-03 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2023-12-28 | 4 | Applied Molecular Transport Inc. (AMTI) | Disposition to issuer (D): 60,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 | EDGAR |
| 2023-09-14 | 4 | GENELUX Corp (GNLX) | Sale (S): 900 @ $20.78 | EDGAR |
| 2023-09-13 | 4 | GENELUX Corp (GNLX) | Grant/award (A): 6,920 @ $0 · Grant/award (A): 8,447 (derivative) @ $0 | EDGAR |
| 2023-09-05 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2023-06-22 | 4 | eFFECTOR Therapeutics, Inc. (EFTR) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Applied Molecular Transport Inc. (AMTI) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-01-24 | 4 | eFFECTOR Therapeutics, Inc. (EFTR) | Grant/award (A): 36,875 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | eFFECTOR Therapeutics, Inc. (EFTR) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-05-26 | 4 | Applied Molecular Transport Inc. (AMTI) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Applied Molecular Transport Inc. (AMTI) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2021-10-08 | 4 | eFFECTOR Therapeutics, Inc. (EFTR) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-08-27 | 4 | eFFECTOR Therapeutics, Inc. (EFTR) | Grant/award (A): 24,142 · Grant/award (A): 24,142 (derivative) @ $0 · Grant/award (A): 3,556 (derivative) @ $0 | EDGAR |
| 2021-03-11 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Option exercise (M): 500 @ $1.68 · Sale (S): 500 @ $32.90 · Sale (S): 1,250 @ $32.90 · Option exercise (M): 500 (derivative) @ $0 | EDGAR |
| 2021-03-05 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 9,500 @ $0 · Option exercise (M): 12,396 @ $1.68 · Grant/award (A): 28,800 (derivative) @ $0 · Option exercise (M): 12,396 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 773 @ $34.20 | EDGAR |
| 2021-02-12 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Option exercise (M): 750 @ $1.68 · Sale (S): 750 @ $35.64 · Sale (S): 2,000 @ $35.64 · Option exercise (M): 750 (derivative) @ $0 | EDGAR |
| 2021-02-03 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Option exercise (M): 1,250 @ $1.68 · Sale (S): 1,250 @ $35 · Sale (S): 3,750 @ $35 · Option exercise (M): 1,250 (derivative) @ $0 | EDGAR |
| 2021-01-21 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Option exercise (M): 500 @ $1.68 · Sale (S): 500 @ $30 · Sale (S): 1,250 @ $30 · Option exercise (M): 500 (derivative) @ $0 | EDGAR |
| 2020-12-16 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Option exercise (M): 1,500 @ $1.68 · Sale (S): 1,500 @ $30 · Sale (S): 3,750 @ $30 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2020-10-01 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Option exercise (M): 500 @ $1.68 · Sale (S): 500 @ $30 · Sale (S): 1,250 @ $30 · Option exercise (M): 500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1559583 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs